Refugees in Kenya Welcome New Law Allowing Them to Integrate into Economy, Society

In Kenya, refugees and their supporters have welcomed a new law that gives the country’s half a million refugees better access to education and work. The law comes as Kenya plans to close two of the region’s largest refugee camps, which are home to more than 400,000 people.

Willie Rwari, a refugee from Burundi, has been in Kenya for the last seven years without a regular source of income. He holds a diploma in mechanical training from Burundi and an additional one from Kenya. Yet, he has been unable to find steady employment in the country’s capital, Nairobi.

Refugees like him have to make do with what they get, he said.

Rwari said they take up whichever jobs they get, even construction site jobs, because they don’t have the required papers to get jobs they are qualified for. Rwari added that they can’t get the certificate of good conduct papers, the national hospital insurance, the Kenya revenue authority pins, the national social security fund papers. And to get any job here, you must have that.

Rwari’s hopes of getting a decent job now lie with the speedy implementation of the new Refugees Bill that Kenyan President Uhuru Kenyatta recently signed into law.

The law paves the way for refugees to integrate into the Kenyan economy and social life.

Victor Odero of the International Rescue Committee said the new law is a bright spot in the quest for empowering refugees.

“There was no obligation before, certainly not in law, for the state to facilitate the issuance of legal documentation through which then refugees would be able to get economic and social development — basically become self-reliant.” Odero said.

That ability for refugees to participate in Kenyan society has also been welcomed by the United Nations High Commission for Refugees. The agency’s spokesperson in Kenya, Eujin Byun, said this will make the refugees feel valued and dignified in their new homes.

“Integration for refugees is critical,” Byun said. “One because refugees don’t want to be the other, and they want to continue their lives while seeking asylum in the host country until they can return to their country safely.”

The new law comes ahead of the planned closure next year of Kenya’s two largest refugee camps, which together house more than 400,000 people, most from Somalia or South Sudan.

Odero says the law will help make the process of clearing the camps easier.

“Refugee camps are simply unsustainable — people agree on that across the board,” Odero said. “So, the question has been, ‘Where, or can we have a legal framework that gives sufficient anchorage to durable solutions?’ And what we can see from this legislation is that it moves things forward. It is actually progressive.”

The close to half a million refugees in Kenya, just like Rwari, want the law to take effect soon so they can get the chance to earn a decent living outside of the camps.

Source: Voice of America

Migrant Advocates Accuse EU of Flagrant Breaches of Geneva Convention

The migrant crisis on Poland’s border, which Western powers accuse Belarusian leader Alexander Lukashenko of engineering, caught international attention in November. But asylum seekers on the Poland-Belarus border aren’t alone in being shunted back and forth across Europe’s land and sea borders, say rights organizations and other monitors.

Throughout the year, irregular migration to Europe has been increasing, with more than 160,000 migrants entering the European Union this year, mostly through the Balkans and Italy. That’s a 70% jump from 2020, when pandemic travel restrictions are thought to have impacted the mobility of would-be migrants, and a 45% increase over the previous pre-pandemic year.

And with irregular migration picking up again, rights campaigners say the EU and national governments are increasingly skirting or breaking international humanitarian laws in their determination to prevent war refugees, asylum seekers and economic migrants from entering or remaining on the continent.

They say European leaders appear determined to avoid a repeat of 2015, when more than a million asylum seekers from the Middle East, sub-Saharan Africa and central Asia arrived in Europe, roiling the continent’s politics and fueling the rise of anti-migrant political parties.

Reports have multiplied of refugees and migrants being forcibly pushed back over the EU’s external borders. So, too, have reports of refugees being prevented from filing asylum applications. Poland passed a law in August stipulating that migrants who cross the border are to be “taken back to the state border” and “ordered to leave the country immediately,” preventing them from making an asylum application.

Pushbacks breach both European human rights laws and the 1951 Geneva Convention, which outline the rights of refugees as well as the legal obligations of the 146 signatory states to protect them.

Signatory states aren’t allowed to impose penalties on refugees who enter their countries illegally in search of asylum, nor are they allowed to expel refugees (without due process). Under the convention, refugees should not be forcibly returned, technically known as “refoul,” to the home countries they fled. Asylum seekers are meant to be provided with free access to courts, and signatory states are required to offer refugees administrative assistance.

The EU, its border agency, Frontex, and the bloc’s national governments, say they do observe international humanitarian law, but according to several recent investigations by rights organizations, the rules are now being flouted routinely and systematically.

“EU member states have adopted increasingly restrictive and punitive asylum rules and are focusing on reducing migration flows, with devastating consequences,” Amnesty International warned recently.

“We are witnessing tremendous human suffering caused by the EU-Turkey deal and by the EU-Libya cooperation, both of which are leaving men, women and children trapped and exposed to suffering and abuse,” the rights organization says in reference to deals struck with Turkey and Libya to block migrants heading to Europe and readmit them when they are ejected from Europe.

In the case of Libya, migrants are often returned to detention camps run by militias where Amnesty International and others have documented harrowing violations, including sexual violence against men, women and children. In a report published earlier this year, Amnesty noted, “Decade-long violations against refugees and migrants continued unabated in Libyan detention centers during the first six months of 2021 despite repeated promises to address them.”

Lighthouse Reports, a Dutch nonprofit journalism consortium, has documented dozens of instances in which Frontex surveillance aircraft were in the vicinity of migrant boats later intercepted by the Libyan Coast Guard. “There is a clear pattern discernible. Boats in distress are spotted, communications take place between European actors and the Libyan Coast Guard,” Lighthouse researchers said in a report this year.

Frontex has routinely denied the allegations but lawmakers in the European Parliament accused the agency, after a four-month investigation, of failing to “fulfill its human rights obligations.” In the Balkans, the Border Violence Monitoring Network and other NGOs say they have gathered testimony from hundreds of refugees who allege they have been beaten back into Bosnia-Herzegovina across the Croatian border by baton-wielding men whose uniforms bear no insignia.

Europe’s peripheral countries have also been erecting border fences and building walls with the prospects of more Afghan refugees appearing on their borders acting as a spur. Greece has completed a 40-kilometer wall along its land border with Turkey and installed an automated surveillance system to try to prevent asylum seekers from reaching Europe. Other countries are following suit and have been pushing the EU to help with funding.

Critics say the wall-building now contrasts with the criticism European leaders leveled four years ago against then-U.S. President Donald Trump over his plan to build a wall on America’s southern border with Mexico. “We have a history and a tradition that we celebrate when walls are brought down and bridges are built,” admonished Federica Mogherini, then the EU’s foreign policy chief.

While migrant advocates complain of rights violations, calls are mounting in Europe for changes to be made to both the Geneva Convention and the bloc’s humanitarian laws. Critics of the convention say it was primarily drawn up to cope with population displacement in Europe in the wake of the Second World War. They say it fails to recognize the nature and scale of the much more complex migration patterns of the 21st century, which could see numbers swell because of climate change.

Last week in Budapest, Balázs Orbán, a deputy minister in the Hungarian government, said the current EU migration laws should be replaced. The current legal system is “catalyzing the influx of illegal migrants, and not helping to stop them on the borders,” he said. “This framework was created during the time of the Geneva Convention in 1951, when refugees from the Soviet Union needed to be accommodated for. Now, times have changed,” he added.

Source: Voice of America

Seminar to nationals in Israel

Nationals residing in Israel conducted a seminar on 27 November focusing on the objective situation in the homeland as well as regional developments. At the seminar in which hundreds of nationals took part, the Charge d’Affairs at the Embassy of Eritrea in Israel, Mr. Solomon Kinfe, gave an extensive briefing on the overall resilience program being conducted and role of nationals abroad, and on the external interventions that are hampering regional peace and cooperative developments as well as on the integrated effort being undertaken in foiling the conspiracies being encountered.

Participants on their part, indicating that they realize that the challenges being encountered in the region are caused by external interventions, condemned the unjust and unlawful unilateral sanctions the US administration has declared on Eritrea.

The nationals further expressed conviction to reinforce organizational capacity and resilience to foil the external conspiracies against Eritrea and strengthen contribution for the successful implementation of national programs.

In related news, nationals residing in Calgary and Saskatoon, Canada conducted a meeting on reinforcing their organizational capacity and thereby strengthening participation for the successful implementation of the national development drives.

The nationals have also organized memorial services on the passing away of veteran freedom fighters Mr. Alamin Mohammed Seid, PFDJ Secretary, and Brig. General Negash Tesfatsion.

Source: Ministry of Information Eritrea

Eritrea participated at 8th Ministerial Conference of FOCAC

Eritrea’s senior delegation composed of Foreign Minister Osman Saleh and Head of PFDJ Economic Affairs, Mr. Hagos Gebrehiwet, participated at the Forum on China-Africa Cooperation (FOCAC) held in Dakar, Senegal from 29-30 November. The 8th Ministerial Conference of FOCAC was held under the theme “Deepening the Sino-African Partnership and Promoting Sustainable Development to Build a China-Africa Community with Shared Future in the New Era”

The Agenda was to evaluate the implementation of the follow-up actions of the 2018 Beijing Summit and the Situation of China-Africa solidarity against Covid-19, and plan the direction of China-Africa relations in the next three years and beyond.

On the margins of the FOCAC Ministerial Conference, Foreign Minister Osman Saleh met with his Chinese counterpart, Foreign Minister Wangi Yi, while Mr. Hagos also held further discussions with the Chinese Minister of Commerce, Mr. Wang Wentao; and, Vice Minister for Foreign Affairs, Mr. Deng Li.

In all the discussions, the two sides underlined the imperative of bolstering multilateralism; their opposition to interference in internal affairs of sovereign States, and the use of unilateral coercive measures. They also agreed to further expand their bilateral economic cooperation.

Source: Ministry of Information Eritrea

UnionPay International partners with M2M to drive digital transformation in Africa

CASABLANCA, Morocco, Nov. 29, 2021 /PRNewswire/ — UnionPay International (UPI) and M2M jointly announced a partnership to accelerate digital financial transformation in Africa, creating new frontiers by leveraging two entities’ strong core capabilities and footprints.

This partnership sets an ambitious product roadmap that allows M2M to provide innovative and customer-centric payment solutions to support issuers, acquirers, fintechs, processors and aggregators across more than 40 countries worldwide.

“Becoming UPI’s certified Third Party Service Provider (TPSP) is a major milestone underscoring our drive to be a one-stop shop and a service payment platform that truly offer clients solutions covering the entire value chain of payments including issuing, acquiring and processing of expanding UPI’s transactions worldwide”, said Mr Rachid SAIHI, CEO of M2M Group. “Thanks to this partnership, M2M Group will be among the first payments actors in Africa to provide end to end processing solutions for UPI’s transactions”.

“We are delighted to collaborate with M2M to facilitate the digital financial transformation in Africa”, said Mr Luping Zhang, General Manager of Africa Branch, UnionPay International. ” UnionPay International continues to offer high quality, cost-effective, innovative payment services through shared growth in the region and contribute value towards the global payment ecosystem”.

At the forefront of the digital era, M2M Group leverages more than 30 years of worldwide innovation and expertise. M2M Group is a leading software company that provides multichannel electronic payments and eGov solutions and services that enable convenience and trust for anyone, anywhere, anytime, and any device. M2M Group’s solutions address a wide range of applications accelerating digital convergence, enhancing user experience and boosting business agility and profitability. M2M Group is listed on Casablanca’s Stock Exchange.

With over 160 million UnionPay cards issued outside of mainland China, UnionPay has expanded its acceptance network to 180 countries and regions in recent years. At present, UnionPay cards are widely accepted in Africa across all sectors, effectively meeting the diverse purchasing needs of UnionPay cardholders visiting and living on the continent. Over 10 African countries have issued UnionPay cards, including Kenya, Tanzania, Uganda, Ghana, South Africa, eSwatini, Madagascar and Mauritius. The Nilson Report (Issue 1154) shows that UnionPay ranks first among all card schemes in card issuance and transaction volume. UnionPay has launched various innovative payment products in Africa in response to the worldwide digital transformation and financial inclusion.

Adagio Therapeutics Reports That None of the Mutations Present in SARS-CoV-2 Variant, Omicron, Are Associated with Escape from ADG20 Neutralization In Vitro

Additional in vitro studies to determine neutralization activity of ADG20 against Omicron are ongoing

ADG20 EUA submissions planned for prevention and treatment of COVID-19 in mid-2022

Inventory build continues in anticipation of EUA in second half of 2022, with 4 million doses available for distribution over the next two years

WALTHAM, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) — Adagio Therapeutics, Inc., (Nasdaq: ADGI) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today provided information related to the potential of its lead SARS-CoV-2 antibody, ADG20, to address the Omicron SARS-CoV-2 variant, and other known variants of concern. ADG20 is an investigational monoclonal antibody (mAb) product candidate designed to provide broad and potent neutralizing activity against SARS-CoV-2, including variants of concern, for the prevention and treatment of COVID-19 with potential duration of protection for up to one year in a single injection.

“The continued global scale of the COVID-19 pandemic has led to increased levels of immune pressure on the virus, which is driving the emergence of variants containing mutations associated with escape from common classes of neutralizing antibodies induced by natural infection or vaccination. Unlike most antibodies currently available under EUA, ADG20 has been shown to target an epitope that is highly conserved among clade I sarbecoviruses and that is not readily targeted by the endogenous neutralizing antibody response,” said Laura Walker, Ph.D., co-founder and chief scientific officer of Adagio. “Due to the highly conserved and immunorecessive nature of the epitope recognized by ADG20, we expect that ADG20 will retain activity against Omicron, as we have observed in in vitro models with all other variants of concern identified previously. Further, none of the mutations present in the spike protein of the Omicron variant have been associated with escape from ADG20 neutralization.   ADG20 was engineered for potent and broadly neutralizing activity in anticipation of both the rapid antigenic evolution of SARS-CoV-2 and the emergence of future SARS-like viruses with pandemic potential.”

“ADG20 was uniquely designed to combine breadth, potency and duration of protection against SARS-CoV-2 for up to one year in a single injection. We did this anticipating that SARS-CoV-2 would continue to evolve and potentially render some early therapies and vaccines obsolete,” said Tillman Gerngross, Ph.D., co-founder and chief executive officer of Adagio. “Our global clinical trials are advancing with potential EUA submissions in mid-2022 for both prevention and treatment of COVID-19. We continue to engage with the FDA and other regulatory bodies and governmental agencies to discuss potential acceleration of development plans and the need for a portfolio of therapeutic solutions to combat the COVID-19 pandemic.”

Given the significant potential health crisis resulting from the emergence of Omicron, Adagio is undertaking a number of activities to support ADG20’s utility in addressing this newly emerged variant of concern, including:

  • Conducting in vitro studies to evaluate the expected binding and neutralizing activity of ADG20 against Omicron. Initial data from these studies is anticipated by the end of the year; and
  • Recruiting patients in Adagio’s Phase 2/3 COVID-19 treatment trial, known as STAMP, across several clinical sites in South Africa (along with ongoing clinical trial efforts globally) in an effort to generate clinical data for ADG20 against infections due to the Omicron variant.

Based on the data being generated, Adagio plans to engage with health authorities and government agencies to accelerate development and supply of ADG20 to combat SARS-CoV-2 and its variants of concern.

ADG20 and Variants of Concern
The neutralizing antibody response induced by SARS-CoV-2 infection and vaccination is dominated by three classes of receptor binding domain (RBD)-directed antibodies (Class 1, Class 2 and Class 3), which often share common escape mutations. The newly emerged Omicron (B.1.1.529) variant identified in South Africa contains mutations associated with resistance to a large proportion of these commonly elicited antibodies, which may be due to immune pressure on these antigenic sites. Data for most antibodies available under EUA or in late-stage clinical development show they target one of these three dominant antigenic regions within the RBD.

In vitro studies have shown that ADG20 binds to a highly conserved epitope within the RBD that is not targeted by any of the common classes of neutralizing antibodies induced by SARS-CoV-2 infection and vaccination. Thus, unlike many other clinical-stage antibodies, which were isolated from COVID-19 patients and recognize epitopes that are also targeted by endogenous neutralizing antibodies, there is limited immune pressure on the ADG20 binding site. The ADG20 epitope has remained conserved in 99.99% of the nearly 4 million full length SARS-CoV-2 viral sequences deposited in the GISAID database as of October 15, 2021, and, as shown in in vitro studies, ADG20 retains activity against prior variants of concern including Alpha, Beta, Delta, and Gamma. For the Omicron variant, none of the mutations present in the spike protein are associated with escape from ADG20 neutralization. Based on published epitope mapping and structural studies, Adagio anticipates that ADG20 will retain neutralizing activity against the Omicron variant whereas other mAb products may lose substantial activity against this variant.

Previously disclosed in vitro data demonstrated retained neutralizing activity of ADG20 against a diverse panel of circulating SARS-CoV-2 variants, including the recently emerged Lambda, Mu and Delta plus variants. Notably, findings from these in vitro studies showed that ADG20 demonstrated potent neutralizing activity against all SARS-CoV-2 variants of concern tested, including those with reduced susceptibility to mAb products currently available under EUA or in late-stage development.

About ADG20
ADG20, an investigational monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses, is advancing through global clinical trials for the prevention and treatment of COVID-19, the disease caused by SARS-CoV-2. ADG20 was designed and engineered to possess high potency and broad neutralization activity against SARS-CoV-2 and additional clade 1 sarbecoviruses by targeting a highly conserved epitope in the receptor binding domain. ADG20 was further engineered to provide an extended half-life for durable protection. ADG20 has demonstrated potent neutralizing activity against the original SARS-CoV-2 virus, SARS-CoV-2 variants of concern Alpha, Beta, Delta, and Gamma, other SARS-CoV-2 variants to date, and additional SARS-like viruses in preclinical studies. ADG20 is administered in clinical trials by a single intramuscular injection. To date, ADG20 has been well-tolerated in a Phase 1 trial with no safety signals identified through a minimum of three months follow-up across all cohorts. ADG20 has not been approved for use in any country, and safety and efficacy have not yet been established.

About Adagio Therapeutics
Adagio (Nasdaq: ADGI) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, including COVID-19 and influenza. The company’s portfolio of antibodies has been optimized using Adimab’s industry-leading antibody engineering capabilities and is designed to provide patients and clinicians with the potential for a powerful combination of potency, breadth, durable protection (via half-life extension), manufacturability and affordability. Adagio’s portfolio of SARS-CoV-2 antibodies includes multiple non-competing, broadly neutralizing antibodies with distinct binding epitopes, led by ADG20. Adagio has secured manufacturing capacity for the production of ADG20 with third-party contract manufacturers to support the completion of clinical trials and initial commercial launch, ensuring the potential for broad accessibility to people around the world. For more information, please visit www.adagiotx.com.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” “intends,” “projects,” and “future” or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning, among other things, the timing, progress and results of our preclinical studies and clinical trials of ADG20, including the timing of our planned EUA submissions, initiation, modification and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs; the expected neutralizing activity of ADG20 against the Omicron variant; our ability to obtain and maintain regulatory approvals for, our product candidates; our ability to identify patients, including in specific populations, with the diseases treated by our product candidates and to enroll these patients in our clinical trials; our expectations regarding the scope of any approved indication for ADG20; and the risk/benefit profile of our product candidates to patients; our manufacturing capabilities and strategy, including plans for doses available in the near future; and our ability to successfully commercialize our product candidates. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from the results described in or implied by the forward-looking statements, including, without limitation, the impacts of the COVID-19 pandemic on our business, clinical trials and financial position, unexpected safety or efficacy data observed during preclinical studies or clinical trials, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, and the uncertainties and timing of the regulatory approval process. Other factors that may cause our actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading “Risk Factors” in Adagio’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2021 and in Adagio’s future reports to be filed with the SEC, including Adagio’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021. Such risks may be amplified by the impacts of the COVID-19 pandemic.  Forward-looking statements contained in this press release are made as of this date, and Adagio undertakes no duty to update such information except as required under applicable law.

Contacts:
Media Contact:
Dan Budwick, 1AB
Dan@1abmedia.com

Investor Contact:
Monique Allaire, THRUST Strategic Communications
monique@thrustsc.com

Officials in Uganda Dismiss Report Country Could ‘Lose’ Airport to China

Ugandan officials are rejecting reports that China could take control of the country’s only international airport because of a failure to honor a loan agreement. China’s embassy in Uganda also dismissed the report. But analysts note the loan deal could become a problem if Uganda ever has trouble paying it back.

Local media reports had indicated that Uganda risked losing its only international airport to China over a $200 million loan to expand the facility.

According to documents shared with local media, China rejected Uganda’s request to re-negotiate some clauses in the 2015 loan deal.

This included a clause that required Uganda’s civil aviation authority to set up an escrow account to hold all of its revenues. Under the clause, the revenues in this account cannot be spent by the aviation authority without approval from Beijing.

Vianney Luggya, the Uganda Civil Aviation Authority spokesperson, told VOA that the Ugandan government has no intention of defaulting on loan repayments to China.

“It is not true that Uganda is going to lose Entebbe International Airport in any way whatsoever. This is not the first time that this allegation is coming up. Uganda is not about to default in honoring the loan obligation. We are still within a grace period of seven years and during that period we have been paying interest,” said Luggya.

The loan agreement also gives China’s Export-Import Bank oversight over monthly operating budgets for the airport.The bank is also authorized to inspect both the Aviation Authority and Ugandan government books of accounts, which some see as eroding the sovereignty of the state.

When VOA contacted the Chinese Embassy in Uganda, they said they were not in position to comment and referred VOA to a statement they issued Sunday.

In the statement, the embassy said the loan agreement between China Exim Bank and Uganda was signed voluntarily through dialogue and negotiation on equal footing without any hidden terms or political conditions attached.

They said China-Uganda economic and trade cooperation and financing in the field of large-scale infrastructure follows the principle of equality and mutual benefit and has been conducted in accordance with the laws and rules of the international market and strictly abided by the laws of the host country.

Economic analyst Fred Muhumza explains that technically, any loan received from an EXIM Bank is not treated as a loan but as an export, thus making it difficult to renegotiate.

Muhumuza said it is time for the government and its lawyers to re-examine how it handles its agreements with donors.

“These loans are reviewed by solicitor general’s office, who are the lawyers. It also indicates, in case of arbitration, we go to China. We are really at the mercy of China. They have an upper hand on this,” he said.

Uganda currently owes China $1.6 billion in loans extended to the East African country for financing of major infrastructure development projects.

In a 2018 report, Uganda’s auditor general raised concern that Uganda had agreed to several stringent conditions in the loans and these had not only increased the cost of borrowing but also exposed Uganda’s sovereignty to risk.

Source: Voice of America